1
|
Fukumoto C, Sawatani Y, Shiraishi R, Zama M, Shimura M, Hasegawa T, Komiyama Y, Fujita A, Wakui T, Kawamata H. Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single-center retrospective cohort study. Invest New Drugs 2021; 39:846-852. [PMID: 33449240 PMCID: PMC8068704 DOI: 10.1007/s10637-021-01062-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 01/01/2021] [Indexed: 11/26/2022]
Abstract
A retrospective cohort study was performed to investigate the effectiveness of preemptive postsurgical therapy with cetuximab for patients with a major risk of recurrence or metastasis after clinical complete resection of primary oral squamous cell carcinoma (OSCC). The study period was from 2007 to 2019 for patients treated at the Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine. OSCC patients with major risk (n = 88) in the follow-up period were divided into groups with no postsurgical treatment (NP group), with standard postsurgical treatment (SP group), and with postsurgical treatment including cetuximab (CP group), and prognosis were compared among those groups. The 5-year overall survival rate was significantly higher in patients who received postsurgical treatment with cetuximab (CP) compared to that in the other two groups ((CP vs. NP, p = 0.028; CP vs. SP, p = 0.042). Furthermore, we performed multivariate analysis to evaluate the effects of the main components of the treatment. Among CDDP, radiotherapy, and cetuximab, only cetuximab significantly contributed to improved survival by univariate analysis (crude HR:0.228, 95%CI:0.05-0.968, p = 0.045). cetuximab also showed the same tendency in multivariate analysis, although p value did not reach significant level (Adjusted HR: 0.233, 95%CI: 0.053-1.028, p = 0.054). The results suggest that the postsurgical treatment with cetuximab as a preemptive postsurgical therapy after complete surgical resection of a visible tumor is considerably effective for OSCC patients with major risk, in other words, invisible dormant metastasis.
Collapse
Affiliation(s)
- Chonji Fukumoto
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Yuta Sawatani
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Ryo Shiraishi
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Manabu Zama
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Michiko Shimura
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Tomonori Hasegawa
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Yuske Komiyama
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
- Department of Dentistry, Oral and Maxillofacial Surgery, Sano Kosei General Hospital, 1728 Horigome, Sano, Tochigi, 327-8511, Japan
| | - Atsushi Fujita
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Takahiro Wakui
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan
| | - Hitoshi Kawamata
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, Shimo-Tsuga, 321-0293, Japan.
| |
Collapse
|
2
|
Sawatani Y, Komiyama Y, Nakashiro KI, Uchida D, Fukumoto C, Shimura M, Hasegawa T, Kamimura R, Hitomi-Koide M, Hyodo T, Kawamata H. Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro. Int J Mol Sci 2020; 21:E6292. [PMID: 32878053 PMCID: PMC7503545 DOI: 10.3390/ijms21176292] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 08/27/2020] [Accepted: 08/28/2020] [Indexed: 01/22/2023] Open
Abstract
Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells.
Collapse
Affiliation(s)
- Yuta Sawatani
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Yuske Komiyama
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
- Section of Dentistry and Oral and Maxillofacial Surgery, Sano Kosei General Hospital, 1728 Horigomecho, Sano, Tochigi 327-8511, Japan
| | - Koh-ichi Nakashiro
- Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan; (K.-i.N.); (D.U.)
| | - Daisuke Uchida
- Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan; (K.-i.N.); (D.U.)
| | - Chonji Fukumoto
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Michiko Shimura
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Tomonori Hasegawa
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Ryouta Kamimura
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Masayo Hitomi-Koide
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Toshiki Hyodo
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| | - Hitoshi Kawamata
- Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Shimo-tsuga, Tochigi 321-0293, Japan; (Y.S.); (Y.K.); (C.F.); (M.S.); (T.H.); (R.K.); (M.H.-K.); (T.H.)
| |
Collapse
|
3
|
Omotehara F, Kawamata H, Uchida D, Hino S, Nakashiro K, Fujimori T. Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line. Br J Cancer 2002; 87:1042-6. [PMID: 12434298 PMCID: PMC2364327 DOI: 10.1038/sj.bjc.6600592] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2002] [Revised: 08/06/2002] [Accepted: 08/15/2002] [Indexed: 11/10/2022] Open
Abstract
We previously demonstrated that a differentiation inducing drug, vesnarinone induced the growth arrest and p21(waf1) gene expression in a human salivary gland cancer cell line, TYS. In the present study, we investigated the mechanism of the induction of p21(waf1) gene by vesnarinone in TYS cells. We constructed several reporter plasmids containing the p21(waf1) promoter, and attempted to identify vesnarinone-responsive elements in the p21(waf1) promoter. By the luciferase reporter assay, we identified the minimal vesnarinone-responsive element in the p21(waf1) promoter at -124 to -61 relative to the transcription start site. Moreover, we demonstrated by electrophoretic mobility shift assay that Sp1 and Sp3 transcription factors bound to the vesnarinone-responsive element. Furthermore, we found that vesnarinone induced the histone hyperacetylation in TYS cells. These results suggest that vesnarinone directly activates p21(waf1) promoter via the activation of Sp1 and Sp3 transcription factors and the histone hyperacetylation in TYS cells.
Collapse
Affiliation(s)
- F Omotehara
- Department of Surgical and Molecular Pathology, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan
| | | | | | | | | | | |
Collapse
|